

- Porphyria cutanea tarda (PCT), 2530
 clinical features of, 436e-5f, 2523t, 2530, 2530f
 diagnosis of, 2523t, 2530
 differential diagnosis of, 362
 genetic considerations in, 367e-7, 390, 2530
 HCV infection and, 367e-3, 2041
 hepatocellular carcinoma and, 545, 545t, 2530
 pathogenesis of, 2522f
 photosensitivity in, 390
 risk factors for, 2530
 skin manifestations of
 blistering lesions, 2530, 2530f
 hyperpigmentation, 360, 360t, 390, 436e-5f
 vesicles/bullae, 361t, 362, 367e-3, 390, 436e-5f
 treatment of, 367e-3, 390, 2530–2531
- Porphyrinogens, 2524
- Porphyrins, 103e-5, 390
- Porphyromonas* spp., 1094
- Porphyromonas* spp. infections. *See also*
 Anaerobic bacterial infections, mixed
 of bone, 1099
 in dog-bite wound, 167e-1
 in human bite-wound, 167e-2
- Portal hypertension
 ascites in, 287, 2063, 2064. *See also* Ascites
 in cirrhosis, 2058
 classification of, 2063t
 clinical features of, 2063
 definition of, 2062–2063
 diagnosis of, 2063
 esophageal varices in. *See* Esophageal varices
 etiology of, 2063
 gastrointestinal bleeding in, 277, 2063. *See also*
 Esophageal varices
 in hepatocellular carcinoma, 545
 pulmonary hypertension and, 1658
 splenomegaly and hypersplenism in, 2064
- Portuguese man-of-war envenomation, 2738
- Posaconazole
 for *Aspergillus* infections, 1349t
 for *Blastomyces* infections, 1339
 for *Candida* prophylaxis, 1253t, 1345
 for *Coccidioides* infections, 1336
 for fungal infections in cancer patient, 491
 for *Fusarium* infection, 1356
 indications for, 1331
 for mucormycosis, 1353
- Positional cloning, 441
- Positive economics, 15e-3
- Positive end-expiratory pressure (PEEP), 1738.
See also Mechanical ventilation
- Positive predictive value (PPV), 479, 479t
- Positive-strand genome, 214e-1
- Positron emission tomography (PET)
 in adrenocortical carcinoma, 2322, 2323f
 in cardiac disease
 infective endocarditis, 270e-24, 270e-25f
 ischemic heart disease, 1582, 1584f
 for myocardial perfusion imaging, 270e-3.
 See also Myocardial perfusion imaging
 in fever of unknown origin, 140–141
 in lung cancer, 513, 1666
 in medullary thyroid carcinoma, 2341f
 in MEN 2A, 2341f
 in musculoskeletal disease evaluation, 2225
 in neurologic disease, 440e-8–9
 cluster headache, 2590f
 dementia, 174, 175f
 migraine, 2589, 2589f, 2590f
 PD, 2609, 2611f
 stroke, 2581
 in osteomyelitis, 840
 in pancreatic cancer, 555
 principles of, 440e-8–9
 in respiratory disease, 1666
 in sarcoidosis, 2209, 2209f
 in solitary pulmonary nodule, 1666
 in tumor detection, 102e-12
- Postal workers, anthrax exposure in, 261e-2
- Postganglionic septiceimia. *See* Lemierre's disease/
 syndrome
- Postantibiotic effect, 935
- Postcardiac injury syndrome, 1575
- Postcoital contraception, 2391
- Postconcussion syndrome, 457e-5, 471e-3,
 471e-5–6
- Posterior cerebral artery
 fetal, 2574
 lesion in territory of, 179, 183
 occlusion of, 199, 2574–2575, 2575f, 2580f
 territory of, 2572f, 2575f
- Posterior column-medial lemniscal pathway,
 158, 159f
- Posterior cortical atrophy syndrome, 182
- Posterior fossa brain tumor, 108
- Posterior pituitary
 disorders of
 diabetes insipidus. *See* Diabetes insipidus
 (DI)
 hypodipsic hypernatremia. *See* Hypodipsic
 hypernatremia
 hormone production in, 2274. *See also*
 Arginine vasopressin (AVP); Oxytocin
- Posterior reversible encephalopathy syndrome
 (PRES), 1793, 2568, 2584
- Postexposure prophylaxis (PEP)
 HBV, 2021–2022
 HIV, 918, 1222, 1283
 measles, 1298
 rabies, 1303–1304, 1304f
 VZV, 917, 1186, 1186t
- Postextrasystolic beat, 254
- Postextrasystolic potentiation, 254
- Postherpetic neuralgia, 215e-8, 237, 1185, 1186,
 2685
- Postictal state, 1773
- Postmenopausal hormone therapy, 2382
 adverse effects of, 744, 2498, 2498f
 approach to the patient, 2386, 2387f
 benefits of, 2383, 2383t
 breast cancer risk and, 524, 2383, 2498f
 cognitive function and, 6e-2, 2386–2387
 colorectal cancer risk and, 478, 539, 2385
 coronary heart disease and, 6e-3, 291e-7–8,
 2385, 2498f
 endometrial cancer and, 596, 2383, 2386
 fracture reduction due to, 2498, 2498f
 gallbladder disease and, 2385
 health status changes after discontinuation
 of, 2386
 lipoprotein disorders and, 2443–2444
 ovarian cancer and, 2386
 risk-benefit profile, 2384t, 2386
 short-term vs. long-term use of, 2386
 stroke risk and, 2498f
 VTE and, 2383, 2498f
- Postnasal drip, 244
- Postoperative period
 acute kidney injury in, 1802–1803
 nausea and vomiting in, 259
- Postparalytic syndrome, 1733
- Postpartum period
 depression in, 6e-5
 DVT in, 47
 hemorrhage in, 403–404
 infections in, 50, 1165
 thyroiditis in, 2299
- Postpolio syndrome, 1291
- Post-premature ventricular contraction, 51e-8
- Poststreptococcal glomerulonephritis
 clinical features of, 233, 1835t, 1836t, 1837
 epidemiology of, 1837
 etiology of, 1837
 pathophysiology of, 1837, 1837f
 renal biopsy in, 62e-2f, 1837
 treatment of, 1837
- Posttest probability of disease, 22, 23f
- Postthrombotic syndrome, 1631, 1631f, 1634
- Posttranslational processing, 427, 428f
- Posttraumatic stress disorder (PTSD)
 clinical features of, 2712
 definition of, 471e-2
 diagnosis of, 471e-2–3, 2713t
 pathophysiology of, 471e-2, 2712
 treatment of, 471e-4–5, 2712–2713
 in war veterans, 471e-2–3
- Postural control, 162
- Postural hypotension. *See* Orthostatic
 hypotension
- Postural orthostatic tachycardia syndrome
 (POTS), 1477, 2642–2643
- Postwar symptoms. *See* War veterans
- Potassium, 304
 in cardiac contraction, 265e-6
 in chronic kidney disease, 333e-2–3, 1814
 depletion of, 305–306, 322
 excess intake of, 35, 310
 parenteral requirement for, 98e-5t
 recommended intake of, 95e-2t
 renal transport of, 332e-5f, 332e-9
 in specialized nutritional support formulas,
 98e-5
 transport and reabsorption of, 296–297, 297f,
 304–305
- Potassium balance, 304–305
- Potassium bicarbonate, for hypokalemia, 307
- Potassium-binding resin, for hyperkalemia,
 64e-3, 1815
- Potassium channels
 ATP-sensitive, 2402, 2402f
 cardiac, 273e-1f, 273e-2, 273e-2f
 muscle, disorders of, 462e-17t, 462e-18
 in seizure initiation, 2547
- Potassium chloride (KCl)
 administration guidelines, 308
 adverse effects of, 308, 310, 644t
 for diabetic ketoacidosis, 64e-1
 for hypokalemia, 64e-7, 307–308
 for hypokalemic periodic paralysis, 462e-17
- Potassium citrate, 307, 431e-5
- Potassium-competitive acid pump antagonists,
 1921
- Potassium hydroxide (KOH) wet-mount
 preparation, 150e-1, 341
- Potassium iodide (KI)
 adverse effects of, 1354
 for radioactive iodine exposure, 263e-6t,
 263e-7
 for *Sporothrix* infections, 1354, 1354t
 for thyroid storm, 2297
- Potassium perchlorate, 2300
- Potassium phosphate, 64e-2
- Potassium-sparing diuretics, 332e-9, 1815
- Potato riddler's lung, 1681t
- Potency, of stem cells, 453
- POTS (postural orthostatic tachycardia
 syndrome), 1477, 2642–2643
- Pott's disease, 117, 836, 852, 1110, 1111f
- Pott's puffy tumor, 227
- Pou5f1* (*Oct4*) gene, 454, 455
- Pouchitis, 1960, 1962–1963
- Poultry worker's lung, 1681, 1681t
- Poverty, health and, 9. *See also* Low- and
 middle-income countries
- Powassan virus, 1307t, 1315
- Powassan virus encephalitis, 1152
- Power law, 86e-6–7
- Power law distribution, 87e-1–2, 87e-2f
- Power of attorney for health care, 59
- Poxviruses. *See also specific viruses*
 gene expression and replication in, 214e-4–5
 host defense inhibition by, 214e-8
 human infections caused by, 220e-1–2,
 220e-1t
 protein functions in, 214e-6
 structure of, 214e-2t, 214e-3f
- PPAR-alpha agonists, 291e-6
- PPARγ (peroxisome proliferator-activated
 receptor γ), 96e-6, 415e-2, 1959
- PPD. *See* Purified protein derivative (PPD)/
 tuberculin skin test (TST)
- PPHP (pseudopseudohypoparathyroidism), 430,
 2485, 2486t
- PPIs. *See* Proton pump inhibitors (PPIs)
- PPKARIA gene mutations, 2344
- PPNAD (primary pigmented nodular adrenal
 disease), 2314, 2343
- PPomas (pancreatic polypeptide-secreting
 tumors), 559t, 2338
- PPOX gene, 2523t
- PPV (positive predictive value), 479, 479t